Formerly known as idiopathic thrombocytopenic purpura, immune thrombocytopenia (ITP) is an acquired autoimmune condition characterized by increased platelet destruction and impaired platelet ...

SAN DIEGO -- Treatment with eltrombopag (Promacta) for pediatric patients with newly diagnosed immune thrombocytopenia (ITP) led to a significantly higher rate of durable platelet response compared ...

Adding ianalumab to standard-of-care second-line eltrombopag prolonged the time to treatment failure vs placebo plus eltrombopag in patients with primary immune thrombocytopenia (ITP) in the pivotal ...

Ianalumab prolonged the duration of safe platelet levels during and after treatment in patients with primary immune thrombocytopenia (ITP) previously treated with corticosteroids1,2 Patients treated ...

Improvements in all HRQoL measures from the end of ADVANCE IV were observed in both the efgartigimod treatment or cross-over to efgartigimod groups of the study. Patients with primary immune ...

Findings showed that treatment with Vyvgart Hytrulo did not meet the primary endpoint of sustained platelet count response compared with placebo. Topline results were announced from a phase 3 trial ...

ATLANTA, Dec. 9, 2019 /PRNewswire/ -- UCB, a global biopharmaceutical company, today announced positive results from a Phase II study (TP0001; NCT02718716) of its novel, first-in-class subcutaneous ...

Most experts would treat you for one to two weeks, then taper the medicine off over a few weeks. The side effects of this dose of steroids are modest if it does not need to be frequently repeated.

Sanofi ($SNYNF) announced an update on their ongoing clinical study. Study Overview Sanofi has completed an observational study titled “Cognitive ...

Basel, August 12, 2025 – Novartis today announced positive top-line results from VAYHIT2, a Phase III trial evaluating ianalumab plus eltrombopag in patients with primary immune thrombocytopenia (ITP) ...